Breaking News

Inotek Appoints CEO

August 13, 2014

Southwell to lead efforts to advance trabodenoson

David. P. Southwell has been named president and chief executive officer of Inotek Pharmaceuticals, Inc., and will also join the board of directors. Mr. Southwell has more than 20 years of experience in pharma and biopharma including financings, mergers and acquisitions, and general corporate leadership.
Prior to joining the company, he served as executive vice president and chief financial officer of Human Genome Sciences (acquired by GlaxoSmithKline in 2012). Before joining the management team of Human Genome Sciences, he served on the company’s board of directors. Previously, Mr. Southwell was executive vice president and chief financial officer of Sepracor Inc., a position he held for 14 years.
“I am excited to be joining Inotek at this time of significant upcoming value inflection points,” said Mr. Southwell. “The company’s lead product, trabodenoson for the treatment of glaucoma, is poised to move into Phase III trials later this year. To date, trabodensoson has shown an excellent safety and efficacy profile in the clinic and is a promising candidate for glaucoma patients. I’m looking forward to joining a leadership team that I have successfully worked with in the past so that we may advance trabodenoson through the clinic and toward marketing approval.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.